ReviewCold Spring Harbor perspectives in medicine2014
MYC association with cancer risk and a new model of MYC-mediated repression.
Review in Cold Spring Harbor perspectives in medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Tumor heterogeneity: development, mechanisms, and therapeutic implications.Signal transduction and targeted therapy · 2026Review
- Integrative Multi-Omics Analysis of Oncogenic EZH2 Mutants: From Epigenetic Reprogramming to Molecular Signatures.International journal of molecular sciences · 2023Article
- Identification of a novel MYC target gene set signature for predicting the prognosis of osteosarcoma patients.Frontiers in oncology · 2023Article
- CCAT 1- A Pivotal Oncogenic Long Non-Coding RNA in Colorectal Cancer.British journal of biomedical science · 2023Review
- Clonal selection of stable aneuploidies in progenitor cells drives high-prevalence tumorigenesis.Genes & development · 2021Article
- MYC promotes cancer progression by modulating mEMBO reports · 2021Article
- Promoting roles of long non-coding RNA FAM83H-AS1 in bladder cancer growth, metastasis, and angiogenesis through the c-Myc-mediated ULK3 upregulation.Cell cycle (Georgetown, Tex.) · 2020Article
- Enhancers and MYC interplay in hematopoiesis.Journal of molecular medicine (Berlin, Germany) · 2020Review
- PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression.Theranostics · 2020Article
- CBX6 is negatively regulated by EZH2 and plays a potential tumor suppressor role in breast cancer.Scientific reports · 2019Article
- Deletion of the murine ortholog of the 8q24 gene desert has anti-cancer effects in transgenic mammary cancer models.BMC cancer · 2018Article
- GWAS in childhood acute lymphoblastic leukemia reveals novel genetic associations at chromosomes 17q12 and 8q24.21.Nature communications · 2018Article
- Network analysis revealed aurora kinase dysregulation in five gynecological types of cancer.Oncology letters · 2018Article
- Integrative analysis of RNA polymerase II and transcriptional dynamics upon MYC activation.Genome research · 2017Article
- Novel function of MDA-9/Syntenin (SDCBP) as a regulator of survival and stemness in glioma stem cells.Oncotarget · 2016Article
- MYC cofactors: molecular switches controlling diverse biological outcomes.Cold Spring Harbor perspectives in medicine · 2014Review
- An overview of MYC and its interactome.Cold Spring Harbor perspectives in medicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
MYC is one of the most frequently mutated and overexpressed genes in human cancer but the regulation of MYC expression and the ability of MYC protein to repress cellular genes (including itself) have remained mysterious. Recent genome-wide association studies show that many genetic polymorphisms associated with disease risk map to distal regulatory elements that regulate the MYC promoter through large chromatin loops. Cancer risk-associated single-nucleotide polymorphisms (SNPs) contain more potent enhancer activity, promoting higher MYC levels and a greater risk of disease. The MYC promoter is also subject to complex regulatory circuits and limits its own expression by a feedback loop. A model for MYC autoregulation is discussed which involves a signaling pathway between the PTEN (phosphatase and tensin homolog) tumor suppressor and repressive histone modifications laid down by the EZH2 methyltransferase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.